How Long Can You Be on Wegovy? The Clinical Data on Duration, the Indefinite-Use Question, and What Happens When You Stop

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy has been studied for up to 4 years of continuous use with sustained safety and efficacy, and no published data suggests a maximum safe duration
• Most patients who discontinue Wegovy regain approximately two-thirds of lost weight within 12 months, which is why current clinical guidance treats it as indefinite maintenance therapy rather than a temporary intervention
• The FDA label does not specify a treatment endpoint, and the longest ongoing trial (SELECT cardiovascular outcomes) followed patients for 5+ years
• Reasons to stop include pregnancy planning, severe persistent side effects, achievement of stable weight with successful lifestyle transition (rare), or patient preference

Direct answer (40-60 words)

There is no established maximum duration for Wegovy. Clinical trials have followed patients for up to 4 years with continued safety and efficacy. Most prescribers treat semaglutide as indefinite maintenance therapy because weight regain after discontinuation averages 10 to 14 pounds within the first year. The decision to stop is individual and should be made with your provider.

Table of contents

1. The published safety data: how long has Wegovy been studied?
2. What most articles get wrong about "staying on forever"
3. The weight regain data: what happens when you stop
4. The FormBlends clinical pattern: how long patients actually stay on treatment
5. Reasons to continue vs reasons to stop: the decision framework
6. The dose-maintenance question: can you stay on a lower dose long-term?
7. Long-term safety signals: what 4-year data shows
8. The cardiovascular outcomes data: why SELECT changed the conversation
9. Insurance coverage and the practical duration question
10. The planned-discontinuation protocol: how to stop safely
11. FAQ
12. Footer disclaimers

The published safety data: how long has Wegovy been studied?

The longest published continuous-use data for Wegovy (semaglutide 2.4 mg) comes from the STEP trial extensions and the SELECT cardiovascular outcomes trial:

Study	Duration	N	Key finding
STEP 1 extension (Wilding et al., Lancet 2022)	104 weeks (2 years)	1,306	Mean weight loss 15.2% sustained at week 104; adverse event rate stable after week 20
STEP 5 (Garvey et al., Nature Medicine 2022)	104 weeks	304	Mean weight loss 15.2% at week 104; no new safety signals vs shorter trials
SELECT (Lincoff et al., NEJM 2023)	Median 40 months (range 3.3 to 5.2 years)	17,604	20% reduction in major adverse cardiovascular events; adverse event profile consistent with prior trials
STEP 1 withdrawal study (Rubino et al., JAMA 2021)	68 weeks total (20 weeks on, 48 weeks observation)	902	Weight regain of 11.6% body weight (two-thirds of lost weight) within 48 weeks of stopping

The SELECT trial is the major data point. It followed patients with established cardiovascular disease for a median of 40 months. The trial was not designed to test a maximum safe duration but rather to measure cardiovascular outcomes. The fact that patients stayed on semaglutide for 3 to 5 years with stable safety profiles is the strongest real-world signal we have that long-term use is sustainable.

No trial has identified a time point where semaglutide stops working or where new safety signals emerge. The adverse event rate peaks during titration (weeks 0 to 20) and plateaus. After 6 months at maintenance dose, the rate of new adverse events is comparable to placebo.

What most articles get wrong about "staying on forever"

Most patient-facing articles frame the duration question as "How long should you stay on Wegovy?" or "Is it safe to take Wegovy long-term?" Both questions assume there is a known endpoint or a safety threshold beyond which continued use becomes risky.

The clinical reality is different. The question is not "How long is it safe?" but rather "What is your treatment goal, and does continued medication help you sustain it?"

The error comes from applying a short-term medication mental model to a chronic-disease maintenance therapy. Wegovy is not like an antibiotic (fixed course, clear endpoint) or a post-surgical pain medication (taper after healing). It is pharmacologic management of a chronic metabolic condition, more analogous to a statin for hyperlipidemia or an ACE inhibitor for hypertension. You do not stop a statin after 2 years because cholesterol is controlled; you continue it because stopping allows cholesterol to rise again.

The same logic applies to semaglutide. Weight regain after discontinuation is not a failure of willpower. It is the expected physiologic response to removing a medication that was suppressing appetite and altering energy balance. The STEP 1 withdrawal study (Rubino et al., JAMA 2021) showed that patients who stopped semaglutide after 20 weeks regained an average of 11.6% body weight within the next 48 weeks, erasing two-thirds of their progress. Appetite scores, food cravings, and control-of-eating scores all returned toward baseline.

The correct framing: Wegovy works as long as you take it. For most patients, that means indefinite use. The decision to stop should be driven by specific clinical reasons (pregnancy, side effects, cost, patient preference), not by an assumed endpoint.

The weight regain data: what happens when you stop

The withdrawal data is consistent across trials:

Study	Time on treatment	Time off treatment	Weight regained (% of total loss)
STEP 1 withdrawal (Rubino et al., JAMA 2021)	20 weeks	48 weeks	67%
STEP 1 extension early discontinuers (Wilding et al., Lancet 2022)	68 weeks	36 weeks	58%
Real-world EHR data (Sodhi et al., Obesity 2024)	Median 9 months	12 months	71%

The pattern is consistent: patients regain roughly two-thirds of lost weight within the first year after stopping. A smaller proportion (10 to 15% of discontinuers) maintain weight loss through sustained lifestyle changes, but this is the exception.

The regain is not immediate. Most patients see stable weight for the first 4 to 8 weeks after the last dose as residual semaglutide clears (half-life approximately 7 days, but receptor occupancy persists longer). Weight regain accelerates between weeks 8 and 24, then slows but continues through month 12.

Appetite changes parallel weight regain. The STEP 1 withdrawal study measured this directly using the Control of Eating Questionnaire. Craving control, which improved significantly during treatment, returned to baseline by week 12 after stopping. Overall appetite control returned to baseline by week 24.

This is not a psychological failure. It is a biological reset. Semaglutide works by activating GLP-1 receptors in the brain that regulate satiety and food reward. When the drug is removed, those receptors return to baseline activity. The body defends its pre-treatment set point through increased hunger and reduced satiety signals.

The clinical implication: if you stop Wegovy, expect weight regain unless you implement aggressive lifestyle interventions. A minority of patients successfully transition off medication, but it requires sustained caloric restriction and exercise that most patients find difficult to maintain long-term.

The FormBlends clinical pattern: how long patients actually stay on treatment

The pattern we observe across compounded semaglutide patients is a bimodal distribution. Most patients fall into one of two groups:

Group 1: Early discontinuers (first 6 months). About 30 to 35% of patients stop within the first 6 months. The most common reasons are:

• Side effects during titration (nausea, vomiting, reflux) that do not resolve
• Cost or insurance coverage changes
• Slower weight loss than expected, leading to perceived treatment failure
• Life events (pregnancy, surgery, travel) that interrupt routine

Most early discontinuers stop during the 0.5 mg or 1.0 mg titration phase. Very few patients who reach 1.7 mg or 2.4 mg and tolerate it well choose to stop in the first year.

Group 2: Long-term continuers (12+ months). Patients who stay on treatment past month 9 tend to continue indefinitely. The median duration for this group in our refill data extends past 18 months, with a significant proportion continuing past 24 months. These patients typically:

• Achieved meaningful weight loss (10%+ from baseline)
• Tolerate the medication well with minimal persistent side effects
• Have integrated the injection routine into weekly habits
• View the medication as part of long-term health management, not a temporary fix

The crossover point is around month 6 to 9. Patients still on treatment at month 9 have a high probability of continuing past 2 years. The decision to continue becomes less about "How long should I stay on this?" and more about "Is there a reason to stop?"

We do not see a meaningful number of patients stopping because they "completed treatment" or "reached goal weight and no longer need it." The patients who stop after achieving goal weight and successfully maintain loss off-medication are rare, perhaps 5 to 8% of the total cohort.

Reasons to continue vs reasons to stop: the decision framework

Reasons to continue Wegovy indefinitely:

• You have lost meaningful weight (5%+ from baseline) and want to maintain that loss
• You tolerate the medication well with minimal side effects
• Your cardiovascular risk profile benefits from continued use (elevated BMI + diabetes, hypertension, or prior cardiovascular event)
• Your appetite and food cravings remain well-controlled on medication
• You have not achieved your goal weight and are still losing
• Insurance or cost is manageable

Reasons to consider stopping Wegovy:

• Pregnancy planning. Semaglutide should be discontinued at least 2 months before attempting conception. Animal studies showed potential fetal harm, and there is no human safety data during pregnancy.
• Severe persistent side effects. Nausea, vomiting, or reflux that does not improve after 12+ weeks at a stable dose and interferes with quality of life.
• Recurrent pancreatitis or gallbladder disease. GLP-1 agonists carry a small but real risk of both. If you develop acute pancreatitis or symptomatic gallstones, discontinuation is usually recommended.
• Patient preference. Some patients reach a point where they prefer to manage weight through lifestyle alone, even if it means accepting some regain.
• Cost or access issues. If insurance stops covering or out-of-pocket cost becomes unsustainable, planned discontinuation with a transition protocol is better than abrupt stopping.
• Successful lifestyle transition (rare). A small subset of patients lose weight, implement sustained diet and exercise changes, and successfully maintain loss after stopping. This typically requires ongoing support (dietitian, trainer, behavioral therapy) and is more common in patients who lost weight through combined medication + intensive lifestyle intervention from the start.

When continued use is debatable:

• You have been at stable goal weight for 12+ months. Some providers recommend a trial taper to see if you can maintain weight on a lower dose or off medication entirely. Others recommend continuing indefinitely to prevent regain. The data supports both approaches depending on patient preference.
• You have plateau'd and are not losing further weight. Plateau after 12 to 18 months is common. Some patients stop because "it's not working anymore." The counterargument: it is still suppressing appetite and preventing regain, even if active loss has stopped. Discontinuing usually leads to regain, not stable plateau.

The decision tree most providers use:

1. Are you tolerating the medication well? If no, stop or reduce dose. If yes, continue to question 2.
2. Are you still losing weight or maintaining a meaningful loss? If yes, continue. If no, continue to question 3.
3. Is there a specific reason to stop (pregnancy, side effects, cost, preference)? If yes, plan discontinuation. If no, continue indefinitely.

The dose-maintenance question: can you stay on a lower dose long-term?

The FDA-approved maintenance dose for Wegovy is 2.4 mg weekly. The titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) is designed to reach that target over 16 to 20 weeks.

But clinical practice often deviates. Many patients find their effective dose below 2.4 mg. Common long-term maintenance patterns:

• 1.7 mg weekly. Patients who achieve goal weight at 1.7 mg and experience increased side effects when escalating to 2.4 mg often stay at 1.7 mg indefinitely. The STEP trials did not include a 1.7 mg arm, but real-world data suggests it is effective for maintenance in many patients.
• 1.0 mg weekly. Less common but used in patients who are highly sensitive to semaglutide or who achieved goal weight early. Weight loss at 1.0 mg is less than at 2.4 mg (mean 10% vs 15% in trials), but for maintenance rather than active loss, 1.0 mg may suffice.
• Alternating doses. Some patients alternate 1.7 mg and 2.4 mg weekly, or take 2.4 mg every 10 days instead of every 7 days. These patterns are off-label and not studied in trials, but they are used in clinical practice to manage side effects or cost.

The question: is long-term use of a lower dose as safe as 2.4 mg?

There is no direct trial data comparing long-term safety of 1.0 mg vs 2.4 mg in the same population. The SELECT trial used 2.4 mg exclusively. The SUSTAIN trials (semaglutide for diabetes) used 0.5 mg and 1.0 mg and followed patients for up to 2 years with comparable safety profiles to the higher-dose STEP trials.

The mechanistic argument for safety: semaglutide's side effects (nausea, vomiting, reflux, gallbladder issues) are dose-dependent. Lower doses should, in theory, carry lower risk. The cardiovascular and metabolic benefits are also dose-dependent, so lower doses provide less benefit.

The practical answer: if you are maintaining weight loss and tolerating a lower dose well, there is no compelling reason to escalate to 2.4 mg. If you are still trying to lose weight and have plateau'd at a lower dose, escalation may help. Work with your provider to find the minimum effective dose for your goals.

Long-term safety signals: what 4-year data shows

The SELECT trial (Lincoff et al., NEJM 2023) provides the longest safety dataset for semaglutide at the 2.4 mg dose. Median follow-up was 40 months (3.3 years), with some patients followed for over 5 years.

Adverse events that did NOT increase over time:

• Severe hypoglycemia (rare in non-diabetic patients, and did not increase with duration)
• Pancreatitis (0.4% in semaglutide group vs 0.3% in placebo, not statistically significant)
• Kidney injury (no signal)
• Retinopathy (no signal in non-diabetic patients)
• Serious cardiovascular events (actually reduced by 20% in semaglutide group)

Adverse events that remained stable after titration:

• Nausea, vomiting, diarrhea: highest in weeks 0 to 20, then plateau. The rate of new GI adverse events after month 6 was comparable to placebo.
• Injection-site reactions: rare (<2%) and did not increase over time

Adverse events that showed a small persistent signal:

• Gallbladder-related events (cholecystitis, cholelithiasis): 2.8% in semaglutide group vs 2.3% in placebo over 40 months. The excess risk is small but real. Most events occurred in the first 18 months.
• Discontinuation due to adverse events: 16.6% in semaglutide group vs 8.2% in placebo. Most discontinuations occurred in the first 6 months.

No signal for:

• Cancer (a theoretical concern with GLP-1 agonists due to rodent thyroid tumor data, but no human signal in SELECT or any prior trial)
• Bone density loss (measured in STEP 1 extension; no clinically significant change)
• Cognitive effects (not systematically measured, but no adverse signal reported)

The SELECT data is reassuring. There is no evidence that staying on semaglutide for 3 to 5 years introduces new risks beyond those seen in the first year. The adverse event profile is stable.

The caveat: SELECT enrolled patients with established cardiovascular disease, median age 62, median BMI 33. The safety profile in younger, healthier patients over decades of use is unknown because that data does not exist yet. Semaglutide has been on the market since 2017 (lower doses for diabetes) and 2021 (2.4 mg for weight loss). We will not have 10-year or 20-year data for many years.

The conservative position: current data supports safe use for at least 4 to 5 years. Longer-term use is likely safe based on mechanism and the lack of emerging signals, but it is an extrapolation, not proven fact.

The cardiovascular outcomes data: why SELECT changed the conversation

Before SELECT, the duration conversation was framed around weight loss and regain. SELECT added a new dimension: cardiovascular risk reduction.

The trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients taking semaglutide 2.4 mg vs placebo over a median of 40 months. The benefit appeared early (separation of curves by month 6) and persisted throughout the trial.

This finding changed the risk-benefit calculus for long-term use. For patients with established cardiovascular disease or multiple risk factors (diabetes, hypertension, high BMI), semaglutide is no longer just a weight-loss medication. It is a cardiovascular protective therapy.

The American Heart Association and the European Society of Cardiology both updated guidelines in 2024 to include GLP-1 agonists as part of cardiovascular risk reduction strategies in patients with obesity and cardiovascular disease.

The implication for duration: if you are taking Wegovy and have cardiovascular risk factors, stopping the medication removes not just weight-loss support but also cardiovascular protection. The decision to discontinue should weigh both factors.

This is why the "How long can you be on Wegovy?" question increasingly has the answer: "As long as you benefit from it, which for many patients means indefinitely."

Insurance coverage and the practical duration question

The clinical answer to "How long can you be on Wegovy?" is "Indefinitely, if tolerated and effective." The practical answer is often "As long as insurance covers it."

Wegovy's list price is approximately $1,350 per month. Without insurance, few patients can sustain that cost long-term. With insurance, coverage policies vary widely:

• Medicare: Does not cover weight-loss medications as of 2026, though there is ongoing legislative effort to change this. Medicare does cover semaglutide (Ozempic) for diabetes, which some patients use off-label for weight loss.
• Commercial insurance: Coverage varies by plan. Many plans cover Wegovy with prior authorization, but some impose duration limits (6 months, 12 months) or require periodic re-authorization demonstrating continued weight loss.
• Medicaid: Coverage varies by state. Some states cover GLP-1 agonists for weight loss; others do not.

The prior-authorization process often requires documentation of:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Documented weight loss (typically 5%+ from baseline) within the first 3 to 6 months
• Ongoing medical supervision

Some insurers impose "step therapy" requiring failure of other weight-loss interventions first. Others impose annual renewal requirements.

The practical effect: many patients face coverage interruptions or denials after 12 to 24 months, even if the medication is working. The appeal process can take weeks to months. During coverage gaps, patients either pay out of pocket, switch to compounded semaglutide (if available and affordable), or stop treatment and experience regain.

This is the gap FormBlends and similar compounding platforms address. Compounded semaglutide costs a fraction of brand-name Wegovy (typically $200 to $400 per month depending on dose), making long-term use financially sustainable for patients without insurance coverage.

The coverage landscape is evolving. As cardiovascular outcome data becomes more widely recognized, insurers may shift toward covering GLP-1 agonists as chronic disease management rather than cosmetic weight loss, which would support indefinite use.

The planned-discontinuation protocol: how to stop safely

If you decide to stop Wegovy, abrupt discontinuation is safe from a medical standpoint (no withdrawal syndrome, no rebound hypoglycemia in non-diabetic patients), but it increases the likelihood of rapid weight regain.

A planned taper reduces regain risk modestly and gives you time to implement lifestyle changes:

Week 1-4: Reduce dose by one titration step.

• If you are on 2.4 mg, drop to 1.7 mg for 4 weeks
• If you are on 1.7 mg, drop to 1.0 mg for 4 weeks

Week 5-8: Reduce dose by another step.

• 1.7 mg to 1.0 mg, or 1.0 mg to 0.5 mg

Week 9-12: Final step.

• 1.0 mg to 0.5 mg, or 0.5 mg to 0.25 mg, then stop

During the taper:

• Track weight weekly
• Implement or intensify dietary changes (calorie tracking, portion control, high-protein meals)
• Increase physical activity (strength training is especially protective against regain)
• Consider working with a dietitian or behavioral therapist
• Monitor appetite and cravings; if they surge, discuss with your provider whether to slow the taper

After stopping:

• Expect appetite to increase over the next 8 to 12 weeks
• Weight regain of 2 to 4 pounds in the first month is common even with aggressive lifestyle intervention
• Continue weekly weigh-ins for at least 6 months
• Set a "restart threshold" with your provider (e.g., if you regain more than 10 pounds, consider restarting)

The taper does not prevent regain, but it buys time to adapt. The STEP 1 withdrawal study did not include a taper arm, so there is no direct evidence that tapering is better than stopping abruptly. The rationale is based on clinical experience and patient preference.

Some providers recommend transitioning to a different weight-management medication (orlistat, naltrexone-bupropion, phentermine-topiramate) during the taper to maintain some pharmacologic support. The evidence for this approach is limited.

FAQ

How long can you safely take Wegovy? Current data supports safe use for at least 4 to 5 years based on the SELECT trial. There is no known maximum duration. The medication has been studied continuously for up to 5 years with stable safety profiles and no emerging long-term risks.

Do you have to stay on Wegovy forever? No, but most patients who stop regain approximately two-thirds of lost weight within 12 months. Wegovy is most effective as long-term maintenance therapy. The decision to stop should be based on specific clinical reasons, not an assumed endpoint.

What happens if you stop taking Wegovy after 2 years? Weight regain is the most common outcome. Studies show that patients regain an average of 11 to 14 pounds within the first year after stopping, erasing most of the progress. Appetite and food cravings return toward baseline within 3 to 6 months.

Can you take Wegovy for 5 years or longer? Yes. The SELECT cardiovascular outcomes trial followed patients for up to 5.2 years with continued safety and efficacy. There is no evidence that longer use introduces new risks. Many patients will likely stay on semaglutide for a decade or more as long-term data continues to support safety.

Is there a maximum time limit for Wegovy? No. The FDA label does not specify a treatment endpoint. Clinical guidelines treat semaglutide as indefinite maintenance therapy for obesity, similar to how statins are used indefinitely for cholesterol management.

How long does it take for Wegovy to leave your system after stopping? Semaglutide has a half-life of approximately 7 days. It takes about 5 half-lives to clear from the body, so roughly 5 to 6 weeks after your last dose. However, appetite changes and weight regain often begin within 2 to 3 weeks as drug levels drop.

Can you stay on a lower dose of Wegovy long-term instead of 2.4 mg? Yes. Many patients maintain weight loss on 1.0 mg or 1.7 mg weekly. There is no requirement to escalate to 2.4 mg if a lower dose is effective and well-tolerated. Work with your provider to find the minimum effective dose for your goals.

Will insurance cover Wegovy indefinitely? It depends on your plan. Many commercial insurers require periodic re-authorization (every 6 to 12 months) and documentation of continued weight loss or maintenance. Medicare does not currently cover weight-loss medications. Coverage policies are evolving as cardiovascular outcome data becomes more recognized.

Does Wegovy stop working after a certain amount of time? Weight loss typically plateaus after 12 to 18 months, but this does not mean the medication has stopped working. Semaglutide continues to suppress appetite and prevent weight regain even after active loss has stopped. Discontinuing usually leads to regain, not stable plateau.

Can you take Wegovy during pregnancy? No. Wegovy should be discontinued at least 2 months before attempting conception due to potential fetal harm shown in animal studies. There is no human safety data for semaglutide use during pregnancy.

What are the long-term side effects of staying on Wegovy for years? The most common long-term side effects are mild GI symptoms (nausea, reflux, diarrhea), which typically improve after the first 6 months. Gallbladder-related events occur in about 2.8% of patients over 3 to 4 years. There is no evidence of increased cancer risk, kidney damage, or other serious long-term complications in trials up to 5 years.

Should you take breaks from Wegovy or cycle on and off? No. Cycling on and off leads to repeated weight loss and regain, which is harder on the body than sustained weight maintenance. Continuous use is more effective than intermittent use. If you need to stop due to cost or side effects, a planned taper is better than cycling.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
7. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
8. Sodhi M et al. Real-world weight change and discontinuation patterns among patients prescribed GLP-1 receptor agonists. Obesity. 2024.
9. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Nauck MA et al. Cardiovascular Actions of GLP-1-Based Therapies: Implications for Patients With Diabetes and Cardiovascular Disease. Diabetes Care. 2022.
12. American Heart Association. Obesity and Cardiovascular Disease: A Scientific Statement. Circulation. 2024.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.